Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Synsorb Biotech (T.SYB) -- Ignore unavailable to you. Want to Upgrade?

To: Reuben Levy who wrote (21)	11/26/1998 12:28:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 26

Synsorb Pk With Antibiotics Effective In Prevent Serious E. Coli Infections Calgary, AB -- Nov. 25, 1998 -- Study results, presented at the 28th eastern regional meeting of the Japanese Society of Nephrology, show that Synsorb Biotech Inc.'s Synsorb Pk (TAK-751S in Japan) co-administered with antibiotics was considered to be safe and effective in preventing the development of serious complications from enterohemorrhagic E. coli infections, such as hemolytic uremic syndrome (HUS). The study was part of a global effort focused on the development of Synsorb Pk, the first and only product being tested in clinical trials to treat pediatric Enterohemorrhagic E. coli (EHEC) infections (including E. coli O157:H7). Dr. Hiroshi Ito, principal investigator, presented the results of the study which was carried out in Japan from June 1997 to February 1998. Initially, 128 children aged six months to 15 years with symptoms of EHEC infection were enrolled in the trial. The study's final analysis included only those children who were confirmed to have EHEC and were admitted to hospital within four days of the onset of symptoms. The researchers reported that 85 of the 128 children were confirmed positive for EHEC, but only 68 were enrolled within four days of the onset of symptoms. Of these 68 evaluable patients, four (5.9 percent) progressed to HUS. However, three of these four patients did not complete the required course of treatment. The researchers confirmed that of the 65 EHEC positive patients who completed the required treatment course, only one (1.5 percent) progressed to HUS. Previous Japanese studies of EHEC patients treated with antibiotics alone reported a rate of progression to HUS of 15.7 percent. A secondary outcome analysis was also performed which analysed the toxin levels in the patients' stools before and after the administration of Synsorb Pk. The researchers reported that even high levels of free toxin in the stool decreased to below detectable limits after the first day of treatment with Synsorb Pk. Additional stool analysis confirmed that the toxins were absorbed by the Synsorb Pk. Synsorb Biotech Inc. is presently conducting a double-blind, placebo-controlled phase III clinical study of Synsorb Pk in Canada, the United States and Argentina. This pivotal trial is examining the utility of Synsorb Pk without co-treatment with antibiotics in reducing the progression to HUS in children 15 and under.